Levels of neopterin and other inflammatory markers in obese and non-obese patients with polycystic ovary syndrome

Basit Öğe Kaydı
dc.contributor.authorAğaçayak, Elif
dc.contributor.authorTunç, Senem Yaman
dc.contributor.authorSak, Sibel
dc.contributor.authorBaşaranoğlu, Serdar
dc.contributor.authorYüksel, Hatice
dc.contributor.authorTurgut, Abdulkadir
dc.contributor.authorGül, Talip
dc.date.accessioned2024-04-24T17:56:36Z
dc.date.available2024-04-24T17:56:36Z
dc.date.issued2015
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kadın Hastalıkları ve Doğum Ana Bilim Dalıen_US
dc.description.abstractBackground: We aimed to measure the levels of inflammatory markers and neopterin in obese and non-obese patients with PCOS by using 2 separate control groups with matching body mass index (BMI). Material/Methods: A total of 60 women of reproductive age with (n=30) and without (n=30) PCOS were included in this study. Based on their BMI, patients with PCOS were divided into 2 groups as obese (n=15) and non-obese (n=15) PCOS groups. In addition, 2 BMI-matched control groups were formed. Neopterin, tumor necrosis factor-? (TNF-?), interleukin-6 (IL-6), C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (N/L ratio), and vitamin B12 were assessed by complete blood count. Results: No significant difference was found between patients with PCOS and control subjects in neopterin, IL-6, TNF-?, and CRP levels. However, N/L ratio levels were significantly higher (p 0.045) and vitamin B12 levels were significantly lower (p 0.033) in patients with PCOS compared to control subjects. No statistically significant difference was found between obese and non-obese patients with PCOS and control subjects in neopterin, IL-6, TNF-?, and N/L ratio levels. However, CRP levels were significantly higher in obese patients with PCOS compared to obese control subjects (p 0.007). Conclusions: It can be concluded that inflammatory activity is increased in patients with PCOS, can lead to an increased risk for atherosclerosis, and this increase is not caused by obesity but rather by the polycystic ovary syndrome itself. However, studies with larger sample sizes are needed in this area.en_US
dc.identifier.citationAğaçayak, E., Tunç, S. Y., Sak, S., Başaranoğlu, S., Yüksel, H., Turgut, A. ve diğerleri. (2015). Levels of neopterin and other inflammatory markers in obese and non-obese patients with polycystic ovary syndrome. Medical Science Monitor, 21, 2446-2455.
dc.identifier.doi10.12659/MSM.894368
dc.identifier.endpage2455en_US
dc.identifier.issn1234-1010
dc.identifier.pmid26292090
dc.identifier.scopus2-s2.0-84940038840
dc.identifier.scopusqualityQ1
dc.identifier.startpage2446en_US
dc.identifier.urihttps://doi.org/10.12659/MSM.894368
dc.identifier.urihttps://hdl.handle.net/11468/23592
dc.identifier.volume21en_US
dc.identifier.wosWoSIDEksik
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherInternational Scientific Literature Inc.en_US
dc.relation.ispartofMedical Science Monitor
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAbdominalen_US
dc.subjectInflammationen_US
dc.subjectObesityen_US
dc.subjectPolycystic ovary syndromeen_US
dc.titleLevels of neopterin and other inflammatory markers in obese and non-obese patients with polycystic ovary syndromeen_US
dc.titleLevels of neopterin and other inflammatory markers in obese and non-obese patients with polycystic ovary syndrome
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu